Asian Pacific journal of allergy and immunology最新文献

{"title":"Prospective Assessment of Penicillin Allergy (PAPA): Evaluating the performance of penicillin allergy testing and post-delabelling outcomes among Hong Kong Chinese.","authors":"Tin Sum Li, Harris K S Hui, Andy Ka Chun Kan, Maegan H Y Yeung, Jane C Y Wong, Valerie Chiang, Philip Hei Li","doi":"10.12932/AP-270922-1469","DOIUrl":"10.12932/AP-270922-1469","url":null,"abstract":"<p><strong>Background: </strong>Incorrect penicillin 'allergy' labels predispose patients to adverse outcomes but are under-recognised in many Asian countries. Studies on performance and post-delabelling outcomes of penicillin allergy evaluation among Chinese remain scarce.</p><p><strong>Objective: </strong>To evaluate the diagnostic performance of allergy testing and post-delabelling outcomes among Chinese patients in a prospective penicillin allergy cohort - Prospective Assessment of Penicillin Allergy (PAPA).</p><p><strong>Methods: </strong>All adult patients (age ≥ 18 years) who underwent penicillin allergy evaluation between January 2020 to December 2021 were recruited and prospectively reviewed by both medical records and individual interviews at least 6 months after delabelling or allergy confirmation.</p><p><strong>Results: </strong>Out of 372 patients who completed penicillin allergy evaluation, 335 (90%) patients were delabelled. The overall negative predictive value of penicillin skin testing was 95%, but lower for patients with non-immediate type reactions (88%). History of non-immediate symptom onset (OR = 4.501 [95%CI = 2.085-9.716], p < 0.001) and duration since index reaction (OR = 0.942 [95%CI = 0.899-0.987], p = 0.012) were associated with positive skin testing. After at least 6 months, 60 (18%) of de-labelled patients had received penicillins again without any adverse reactions. Fluoroquinolone-use was significantly lower among delabelled patients compared to those with penicillin allergy (38[11%] vs 11[30%], p = 0.004).</p><p><strong>Conclusions: </strong>After at least 6 months, one in six delabelled patients already received penicillins again safely, with significantly lower fluoroquinolone usage. None experienced adverse reactions. History of non-immediate onset and shorter duration since index reaction were associated with genuine allergy. In patients with severe non-immediate reactions, skin tests should be supplemented with thorough clinical history and adjunct diagnostic evaluations.</p>","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":"10-17"},"PeriodicalIF":2.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9661270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autologous stem cell transplantation in a patient with systemic sclerosis-associated interstitial lung disease in Taiwan.","authors":"Yu-Jen Pan, Wei-Han Huang, Kuei-Ying Su","doi":"10.12932/AP-080421-1108","DOIUrl":"10.12932/AP-080421-1108","url":null,"abstract":"<p><strong>Background: </strong>Systemic sclerosis (SSc), characterized by fibrosis of the skin and other organs, is a devastating systemic autoimmune disease. Lung involvement is frequent in SSc and contributes to the high rate of mortality.</p><p><strong>Objective: </strong>To describe the first case report of SSc and interstitial lung disease (ILD) receiving autologous hematopoietic stem cell transplantation (ASCT) in Taiwan.</p><p><strong>Methods: </strong>Case report.</p><p><strong>Results: </strong>A 51-year-old man presented with rapid skin thickening and shortness of breath. Early progressive SSc-associated ILD was diagnosed. Because his lung function rapidly declined and his skin disease progressed, he received ASCT with satisfactory treatment responses in both skin thickness and lung function. In addition, lung imaging analysis showed remarkable improvements in ILD after treatment.</p><p><strong>Conclusions: </strong>We suggest that ASCT can be considered in selected patients with early, rapidly progressive SSc associated with ILD.</p>","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":"106-110"},"PeriodicalIF":2.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39434838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validity and reliability of the Indonesian version of the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL).","authors":"Teffy Nuary, Windy Keumala Budianti, Wresti Indriatmi, Ilaria Baiardini","doi":"10.12932/AP-291220-1024","DOIUrl":"10.12932/AP-291220-1024","url":null,"abstract":"<p><strong>Background: </strong>Assessment of quality of life is needed to assess therapeutic response. There is currently no instrument available for assessing the quality of life of chronic urticaria patients in Indonesia. CU-Q2oL is a specific questionnaire for chronic urticaria that was first developed in Italian. Validity and reliability tests are important to ensure that the language or term used are appropriate to the local culture and there is no change in the validity and reliability of the questionnaire.</p><p><strong>Objective: </strong>The aim of this study is to develop an Indonesian version of CU-Q2oL.</p><p><strong>Methods: </strong>The Italian version CU-Q2oL was translated into Indonesian and underwent cross-cultural adaptation. The translated questionnaire was completed online by 40 chronic urticaria patients of the Dermatovenereology Outpatient Clinic of the Cipto Mangunkusumo General Hospital, Jakarta, Indonesia.</p><p><strong>Results: </strong>Validity test resulted in correlation coefficient values for all questions of 0.467 to 0.856. Reliability test showed a Cronbach's α coefficient of all questions of 0.923 and the intraclass correlation coefficient (ICC) for all questions was 0.913.</p><p><strong>Conclusions: </strong>This study demonstrates that the Indonesian CU-Q2oL questionnaire is valid, reliable, and suitable to assess the quality of life of chronic urticaria patients in Indonesia.</p>","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":"71-75"},"PeriodicalIF":2.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39171672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the clinical performance of four fungus-specific immunoglobulin E detection systems in patients with Aspergillus allergy.","authors":"Zhifeng Huang, Wanjia Li, Hao Chen, Baoqing Sun","doi":"10.12932/AP-161220-1015","DOIUrl":"10.12932/AP-161220-1015","url":null,"abstract":"<p><strong>Background: </strong>Allergic bronchopulmonary aspergillosis (ABPA) is an airway disease caused by Aspergillus (mainly Aspergillus fumigatus).</p><p><strong>Objective: </strong>To evaluate the diagnostic performance of four fungal-related allergen-specific immunoglobulin E (sIgE) detection systems.</p><p><strong>Methods: </strong>A total of 99 patients with ABPA and 30 control patients admitted to the First Affiliated Hospital of Guangzhou Medical University from 2017 to 2019 were included in the study. Four allergen detection systems were used to detect Aspergillus-related sIgE.</p><p><strong>Results: </strong>The 99 patients were divided into two groups based on the total IgE. Fluorescence immunoassay for fungal mixtures detected positive rates of 100% and 81% in the Confirmed and Probable groups, respectively. For Aspergillus fumigatus, the positive rates were 90.2% and 87.9%, respectively. In the detection of sIgE of fungal mixtures in all ABPA patients, the sensitivity of System 1 was 90.9%, which was higher than for the other three systems (System 2, 38.4%; System 3, 44.4%; System 4, 52.5%), All four systems have excellent specificity ( > 90.0%) and had higher consistency in the Confirmed group than in the Probable group (P < 0.05). Consistency for the Aspergillus mixture and Aspergillus fumigatus detected by fluorescence immunoassay was 90.2% and 86.2% in the Confirmed and Probable groups, respectively.</p><p><strong>Conclusions: </strong>Despite the many methods used to detect fungal-related sIgE, the ImmunoCAP system has the best clinical diagnostic performance. It is recommended that this method be used to detect fungal (mixtures or Aspergillus fumigatus) sIgE in order to reduce the missed diagnosis rate of ABPA.</p>","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":"18-24"},"PeriodicalIF":2.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39171745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chimeric peptides targeting the receptor-binding domain of SARS-CoV-2 variants inhibit ACE2 interaction.","authors":"Pisit Ubonsri, Jiraporn Panmanee, Ittipat Meewan, Promsin Masrinoul, Jukrapun Komaikul, Surapon Piboonpocanun","doi":"10.12932/AP-030424-1833","DOIUrl":"10.12932/AP-030424-1833","url":null,"abstract":"<p><strong>Background: </strong>The receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein is pivotal in facilitating viral entry and serves as a major target for vaccine development and therapeutics. Despite undergoing mutations aimed at evading host immunity, certain regions within the RBD remain conserved.</p><p><strong>Objective: </strong>This study aimed to identify peptides capable of interacting with these conserved regions of the RBD across various variants and assess their neutralization potential.</p><p><strong>Methods: </strong>The PhD-12 phage display library underwent screening to identify phages binding to the RBD. Selected phage clones were examined for binding to the RBD of multiple variants, including 2019-nCoV, Delta (B.1.617.2), Omicron (B.1.1.529), and XBB. Peptides, expressed as chimeric constructs, were tested for their binding to the RBD, the Omicron trimeric S, inactivated SARS-CoV-2 virus, and neutralizing activity. The binding sites were analyzed using Molecular Docking.</p><p><strong>Results: </strong>Two selected phage clones displayed peptides binding to the RBD of multiple variants. Chimeric T hioredoxin-peptides (Trx-RB9 and Trx-RB10) exhibited binding to both inactivated SARS-CoV-2 and the Omicron trimeric S, with half-maximum effective concentrations (EC50 ) values of 111.9 and 360.2 nM, respectively. Molecular docking revealed distinct binding sites within the RBD of the Omicron trimeric S for both Trx-RB9 and Trx-RB10. A mixture of Trx-RB9 and Trx-RB10 inhibited 78% of the binding of recombinant human ACE2 to the Omicron trimeric S.</p><p><strong>Conclusions: </strong>The chimeric Trx-RB9 and Trx-RB10 peptides bind to the RBD of SARS-CoV-2 variants and inhibit the binding of ACE2 to the RBD of the Omicron trimeric S.</p>","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":"124-134"},"PeriodicalIF":2.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142709035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Direct healthcare cost comparison of Fluticasone propionate/Salmeterol vs Budesonide/Formoterol Maintenance And Reliever Therapy for moderate/severe asthma: Results from Thailand.","authors":"Torsak Bunupuradah, Watchara Boonsawat, Jatupum Kamrapit, Bhumika Aggarwal","doi":"10.12932/AP-180421-1117","DOIUrl":"10.12932/AP-180421-1117","url":null,"abstract":"<p><strong>Background: </strong>Inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) for moderate/severe asthma i.e. regular Fluticasone propionate/Salmeterol (FP/Salm) with as-needed short acting beta-2 agonist (SABA) or ICS/Formoterol Maintenance And Reliever Therapy (MART) are the recommended options.</p><p><strong>Objective: </strong>To compare healthcare cost between regular FP/Salm with as-needed SABA vs MART in Thailand.</p><p><strong>Methods: </strong>Direct healthcare cost data from 3 published randomized trials in asthma patients aged ≥12 years comparing regular twice-daily FP/Salm with as-needed SABA vs Budesonide/Formoterol (BUD/Form) MART in moderate/severe asthma were considered: AHEAD (NCT00242775/17 countries/2309 patients), COMPASS (AstraZeneca study SD-0390735/16 countries/3335 patients), and COSMOS (AstraZeneca study SD-039-0691/16 countries/2143 patients). Total direct treatment cost comparison/patient/year was calculated as a combination from 1) medication costs plus 2) healthcare utilization costs i.e. cost for health care visit, emergency room visit, and hospitalization. Unit costs referred from National drug information and Health Intervention and Technology Assessment (HITAP), Ministry of Public Health.</p><p><strong>Results: </strong>Annual medication costs of FP/Salm + SABA were lower than MART in all studies with average cost as 182.01 vs 347.21 USD. Average annual healthcare utilization costs were 17.51 vs 13.01 USD in FP/Salm + SABA and MART, respectively. In overall, total direct treatment costs/patient/year with FP/Salm was 199.53 vs 360.22 USD of MART. Percent saving of total direct treatment costs by FP/Salm + SABA was 45% lower than with MART.</p><p><strong>Conclusions: </strong>In moderate/severe asthma patients, total direct treatment costs with regular twice-daily FP/Salm with as-needed SABA were lower than with BUD/Form MART primarily due to lower medication costs. Healthcare cost should be considered for asthma care in Thailand.</p>","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":"65-70"},"PeriodicalIF":2.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39432382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nivolumab-induced diffuse type 2 rhinosinusitis: A case report.","authors":"Firas Kassem, Yossi Rosman, Ilan Blau, Ben Nageris, Anna Zakharov, Ameen Biadsee","doi":"10.12932/AP-240721-1196","DOIUrl":"10.12932/AP-240721-1196","url":null,"abstract":"<p><strong>Background: </strong>Nivolumab, an immune checkpoint inhibitor is used to treat advanced metastatic malignancies. Data showed that nivolumab can cause exacerbated response of T-Helper 2 cells and lead to airway inflammation.</p><p><strong>Objective: </strong>To present the upper airway findings of a 69-year-old woman after treatment with nivolumab.</p><p><strong>Methods: </strong>Case report.</p><p><strong>Results: </strong>A 69-year old woman with no history of chronic rhinosinusitis developed complaints of nasal congestion, rhinorrhea, sneezing, and anosmia. These symptoms started after one year of treatment with nivolumab. Pale polyps were observed on fiberoptic endoscopy examination. A gradual increase in eosinophil blood counts was noted. On histopathology, heavy infiltrates of eosinophils were seen in the tissue.</p><p><strong>Conclusions: </strong>Nivolumab is used to treat various advanced metastatic malignancies, with a good safety profile. Nevertheless, physicians must be alert to the possibility of evolving type II inflammation in patients, as appropriate therapy can be provided to improve their quality of life.</p>","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":"93-96"},"PeriodicalIF":2.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39623418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lessons from Thailand's successful prevention of mother-to-child hepatitis B transmission: Advancing toward elimination by 2030.","authors":"Yong Poovorawan, Phattharaporn Inma, Pornjarim Nilyanimit, Sitthichai Kanokudom, Chatree Jullapetch","doi":"10.12932/AP-220125-2021","DOIUrl":"10.12932/AP-220125-2021","url":null,"abstract":"<p><p>Thailand has achieved remarkable success in preventing and reducing hepatitis B virus (HBV) incidence through its nationwide newborn vaccination program, introduced in 1992 as part of the Expanded Program on Immunization (EPI). Before the vaccination era, HBV endemicity in Thailand was high, with a carrier rate of 6-8%, and mother-to-child transmission was a major route of infection. Early trials demonstrated the efficacy of hepatitis B vaccines, especially when administered within 12 hours of birth, followed by scheduled doses. The national vaccination program was initially piloted in two provinces in 1988 and expanded to full coverage by 1992. By 2024, carrier rates among children under 10 years dropped to less than 0.1%, meeting the WHO goal of zero mother-to-child transmission. Studies confirmed the vaccine's long-term protection, with no cases of chronic infection in vaccinated individuals with detectable anti-HBs over 20 years. Moreover, literature indicates that hepatitis B vaccination provides long-lasting protection more than 35 years. Additional measures, including antiviral use for high-risk mothers and expanded screening and treatment programs, have further supported HBV elimination. The program's impact has significantly reduced liver-related diseases and positioned Thailand as a model for HBV control. As the nation moves toward the 2030 hepatitis elimination goal, ongoing efforts focus on screening older populations with a high prevalence of infection and ensuring treatment access to achieve lasting eradication.</p>","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":"43 1","pages":"1-9"},"PeriodicalIF":2.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143647062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dysbiosis involving methionine and PPAR-γ pathways is associated with early onset atopic dermatitis and food allergy.","authors":"Anchalee Senavonge, Massalin Nakphaichit, Wanwipa Vongsangnak, Sittiruk Roytrakul, Preecha Patumcharoenpol, Amornthep Kingkaw, Chantha Wongoutong, Wanlapa Weerapakorn, Natapol Pornputtapong, Orawan La-Ongkham, Yong Poovorawan, Nasamon Wanlapakorn, Pannipa Kittipongpattana, Sunee Nitisinprasert, Pantipa Chatchatee, Narissara Suratannon","doi":"10.12932/AP-131223-1749","DOIUrl":"https://doi.org/10.12932/AP-131223-1749","url":null,"abstract":"<p><strong>Background: </strong>Atopic dermatitis (AD) and food allergy (FA) often originate early in life. Gut microbiota interactions with the host immune system influence allergy development, yet the distinct gut microbiome and functional profiles in individuals with AD, FA, or both AD+FA remain underexplored.</p><p><strong>Objective: </strong>We investigated microbial colonization and proteomic profiles in infants with AD, FA, and AD+FA compared to age- and sex-matched controls from the Allergy Development in Early Life and Associated Factors in the Thai Birth Cohort (ALICE).</p><p><strong>Methods: </strong>Gut microbiomes from stool samples were analyzed using 16S sequencing, and proteomic analysis was conducted by liquid chromatography-tandem mass spectrometry.</p><p><strong>Results: </strong>The study included 16 AD, 5 FA, 5 AD+FA subjects, and 26 controls. AD+FA group exhibited the most severe dysbiosis. Enrichment of proteins involved in methionine biosynthesis in Bifidobacterium scardovii and high Erysipelotrichaceae colonization suggest a link to high-fat diets, known to reduce intestinal short-chain fatty acid and serotonin levels, contributing to allergies. Erysipelotrichaceae in AD+FA groups also expressed proteins related to histidine degradation. Low Bifidobacteriaceae levels were noted in FA and AD+FA, with more pathogenic strains colonized. Increased Bacteroidaceae in FA and AD+FA and Enterobacteriaceae in FA were detected. Pathways involving vitamin B1, a ligand for proliferator-activated receptor-γ (PPAR-γ) from Enterobacteriaceae could promote TH2 cells, type 2 innate lymphoid cells, and M2 macrophages, likely contribute to allergic inflammation.</p><p><strong>Conclusions: </strong>AD+FA phenotype exhibited the most distinctive gut microbiome alterations, highlighting unique dysbiosis patterns. Microbiome biosynthesis pathways involving metabolism of methionine, histidine, serotonin, and vitamin B1 point to new targets for modifying or treating AD and FA.</p>","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143424849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neuropsychiatric adverse effects of antihistamine: A nationwide data-based epidemiological study in South Korea.","authors":"Jin Youp Kim, Dong Wook Shin, Zio Kim, Su Hwan Kim, Kyung-Lak Son, Su Hwan Kim, Hyung-Jin Yoon","doi":"10.12932/AP-100724-1889","DOIUrl":"https://doi.org/10.12932/AP-100724-1889","url":null,"abstract":"<p><strong>Background: </strong>Despite concerns on the major neuropsychiatric side effects for long-term use of H1-receptor antagonist (anti-histamine, AH), one of the major therapeutic tools for allergic diseases, their association has not been investigated well.</p><p><strong>Objective: </strong>This study aimed to assess the association between AH usage and neuropsychiatric disorder (NPD) incidence using the National Health Insurance Service Database.</p><p><strong>Methods: </strong>This study was conducted using data from the National Health Insurance Service Database from January 1st 2002 through December 31th 2017. To enroll the participants who may have history of long-term use of AH, participants having common allergic diseases were enrolled. We defined NPD as diagnosed by a psychiatrist occurring during and after antihistamine use to 6 months thereafter.</p><p><strong>Results: </strong>A total of 1,488,075 participants were enrolled. No significant association was found between increased AH usage and NPD incidence after adjusting for potential confounding factors in the health screening data. Notably, the 30-89 day AH usage group showed a significantly lower NPD risk in the subgroup analysis in participants aged over 60 years. No other groups within this age category showed a significant increase in risk.</p><p><strong>Conclusions: </strong>This study suggests that long-term AH use does not significantly increase NPD risk. While this study lacked evaluation of mild neuropsychiatric side effects not requiring psychiatric visits, this study may contribute real-world evidence to the understanding of AHs' long-term neuropsychiatric side effects.</p>","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143424851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}